While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni.
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders.
Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer.
Anew Therapeutics Pte Ltd. has discovered new interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye and more.
Thioredoxin reductase 1 (TXNRD1) is a key component of the thioredoxin antioxidant system that helps maintain cellular redox homeostasis and regulates critical cellular processes such as proliferation, apoptosis and immune responses. A team of researchers at Central South University systematically investigated TXNRD1 expression and function in psoriatic keratinocytes using gene expression datasets, clinical samples and in vitro and in vivo models.
Researchers from Chongqing Medical University have presented data regarding an antiviral compound, KM-10411, derived from a FUBP1 inhibitor (FUBP1-IN-1), as a potential approach to treat hepatitis B virus (HBV) infections.
Rani Therapeutics Holding Inc. has entered into a research and development collaboration with Pegbio Co. Ltd. to explore the delivery of multiple candidates from Pegbio’s obesity and metabolic disease pipeline using Rani’s proprietary Ranipill platform.
Apertura Gene Therapy has entered into a cooperative research and development agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute.